

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Application No.: New U.S. Patent Application

Filed: December 21, 2001

Docket No.: 109993

For: GENE THERAPY USING ANTI-GP41 ANTIBODY AND CD4 IMMUNOADHESIN

PRELIMINARY AMENDMENT

Director of the U.S. Patent and Trademark Office
Washington, D. C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please replace claims 15-16 as follows:

15. (Amended) A host cell which comprises at least an expression cassette of claim 2.
16. (Amended) A host cell which comprises at least a vector of claim 4.


REMARKS

Claims 1 - 38 are pending. By this Preliminary Amendment, claims 15-16 are amended to remove multiple dependencies. Prompt and favorable examination on the merits is respectfully requested.

The attached Appendix includes marked-up copies of each rewritten claim (37 C.F.R.

1.121(c)(1)(ii)).

Respectfully submitted,



William P. Berridge
Registration No. 30,024

Melanie L. Mealy
Registration No. 40,085

WPB:MLM/mlb
Attached: Appendix
Date: December 21, 2001

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--

APPENDIX

Changes to Claims:

The following are marked-up versions of the amended claims:

15. (Amended) A host cell which comprises at least an expression cassette ~~selected among the group consisting of an expression cassette of claim 2, the first expression cassette of claim 3 and the second expression cassette of claim 3.~~

16. (Amended) A host cell which comprises at least a vector ~~selected among the group consisting of a vector of claim 4, the first vector of claim 3 and the second vector of claim 3.~~